Category: Industry

  • The right to drive and the right to work

    .

    The below article penned by Perth-based workplace lawyers appeared in the West Australian on 18 August 2023. It catastrophises the brave new world of Medicinal Cannabis permeating our everyday lives, including our working lives.

    It is an interesting piece but also a bizdev exercise that deserves a swift rebuttal from Drive Change alongside some general commentary on a couple of points where we somewhat agree.

    One line medical certificates doled out by telehealth-only operators are not useful in broadening corporate and industrial acceptance of cannabinoid therapeutics. CBD and THC are viable treatment options for people where past use of SSRIs, benzodiazepines, opioids, gabapentinoids and quetiapine (to name but a few other types of impairing drugs) has not alleviated the symptoms being treated or caused intolerable side effects.

    Online-only operators need to go that extra step in dealing with employers. Not ditching patients caught in a bind would be useful also. Providing patients with something more than one line or tangental boilerplate on why you can’t provide a more detailed letter without physical examination. Failing to offer something beyond the bare minimum for telehealth patients caught up in workplace drug testing issues is, being blunt, a dick move.

    In a post-Covid industrial world where battle lines are now being drawn over WFH (work from home), employers also need to get to grips with the fact that many workers utilised the lockdown era as a chance to finally taper off the many prescription drugs that were harming not helping them. Mainly SSRIs if you place any stock in the wonderful world of Reddit and closed social media groups for persons tapering off X drug.

    The lockdown era assisted many in dialling back on poly-pharmacy generally. The chronic-insomniac-in-lockdown had leeway for some intentionally rough nights withdrawing from benzos because they knew that holding it together in a Zoom meeting the following day was doable. But fronting up to the office in person, forget it. The warehouse worker who was reliant on opioids to get through each shift was able to dial back their dose of oxycontin to half (and gradually decreasing). For those enduring SSRIs withdrawals, the privilege of being able to weather acute attacks of the zaps & sweats in the foetal position in your own bed and not a toilet cubicle at the office, was a blessing. WFH enabled many a third or fourth attempt at tapering off to be the final one.

    This growing demographic have either managed the tapering off with zero pharmacological assistance or they have done so with one or a combination of any of the dozens of promising treatments for the above conditions from cannabinoids to psilocybin to MDMA (and anything else likely to be approved by the TGA/FDA in the coming decade).

    So there’s an emerging number of people with THC going into in their system (as prescribed) at some point in any given 24-hour period, in almost every workplace in the country right now.

    How should David Brent/Michael Scott as man on the Clapham Omnibus deal with cases like:

    1. THC prescribed outside of working hours with reasonable reliance to be had on communications from the prescriber as to a minimum 12 hours between onset of impairment and sitting down at their desk the next morning.
    2. A worker disclosing their being prescribed a minimal dose of THC, where the the therapeutic intent is that the effects of CBD are more pronounced when a dash of THC is added (ie someone prescribed a 3:150:50 THC:CBD:CBG and zero prospect of them being even remotely impaired).
    3. Cases dealing with management of physical pain where a very low dose of THC is clinically defensible and no cognitive effects are likely to be discernible.
    4. Cases where a request for use of THC during work hours, on work premises, would on any view of the full facts, be unreasonable.
    5. WFH and daytime dosage prescriptions for THC that, as a result of traditional cannabis stereotypes, causes an employer to raise a concern at the cognitive ability of a worker to perform their obligations and produce deliverables within the timeframe required.

    How to maintain consistency with consumption of alcohol policies / other prescription drugs?

    How to ensure safe workplaces for everyone? Not just Joan for HR or other examples provided, but the people who have to work with them. In Slough UK or Scranton PA, we need a sensible approach to what is essentially, a worker taking their prescribed medication as directed.

    Employers want to head off Van and Munter’s life dream of ripping bongs at work. The tea break was arguably the earliest workplace right achieved in the Industrial Revolution. The owners of the means of production figured out that a caffeine and dopamine boost in the afternoon actually boosted overall productivity and reduced accidents. All that from a plant hey?

    What parameters ought be set around environments where a sudden onset of a moderate to high dose of THC causes a person to become a WHS risk? What arguments in favour are there for such a scenario to be viewed separately from the sudden onset of large amounts of alcohol?

    If Joan from HR is recovering from surgery or managing chronic pain and if Joan does nothing but sit at a desk and work, then the risk level is not the same as office drinks, on office premises. It is certainly possible to take a low dose of THC that treats pain whilst at the same time does not cognitively impair due to being balanced out by other cannabinoids, plus if Joan is a trooper, many years of tolerance. Maybe “the good biscuits with cream” start disappearing from the kitchen at a faster rate. That surely is about the worst of it for Joan.

    We expect employer solicitors will seek to argue that it is an unjustifiable burden on an employer to have people at the risk of known/unknown impairment by way of THC on work premises during any WHS misadventure/event. What is the worst case scenario? Tony from Marketing sprinting back into a fire to rescue the Peanut M&Ms he put in the fridge that morning? Perhaps employers will argue that people who consume THC over time, even at low doses, believe themselves to be inflammable. We don’t really know and we won’t really know until such outlier cases happen, if indeed, they ever do.

    If Joan from HR isn’t impaired by THC then it doesn’t require an extra fire warden to carefully shepherd her down the fire escape even if Joan can’t be designated as one herself.

    However if Joan was WFH and needed to bump up her THC dose a bit higher to manage a flare up and was then physically impaired but capable of working at a keyboard and doing her job, are there any WHS angles that restrict her from doing that?

    These are things we need to figure out so we thank Messrs Kingston Reid for extending the conversation.

    As MC makes further in-roads, employers will, on-the-whole, gradually become more accommodating to it or else it will cost them good employees. It already is. An employer’s level of tolerance to MC will no doubt be connected with any associations (positive or negative) with productivity first and safety second, because that’s how our current economic system rolls.

    Operating vehicles on public roads?

    Let’s start with the one point in this article that we all agree on. Mr Stutley is sort of correct when he says that from a WHS (work health and safety) perspective, where the job role requires driving on public roads or having a clean license then any workplace lawyer looking to argue reasonable accommodations for a worker on prescribed THC is going to be hamstrung by drug driving laws generally IF driving is part of the job or IS the job. This is why Drive Change is branching out into the workplace sphere. There are collaborative solutions to be had by continuing the workplace and MC conversation.

    There are serving police officers in WA, prescribed MC for PTSD who have been accommodated on reasonable adjustments for five years now. They don’t punt them from the force. They just don’t let them drive or do any actual policing whatsoever and restrict them to administrative desk duties. It’s not an ideal life for someone recovering from PTSD caused from being a front line worker but at-least the mortgage keeps getting paid.

    Where “not driving” can be accommodated without an employer incurring a loss, then it ought be a reasonable adjustment in the best interests of retaining a valued employee.

    Employers can’t tell the diff btw prescribed and illicit THC?

    If the worker has a prescription from a doctor stating the workers is prescribed THC then that is the only thing that matters re identifying the source of the THC.

    Would any employer, anywhere in Australia, dare question the providence of opioid metabolites in an employee’s urine where that employee produced medical evidence indicating the drugs were prescribed? No. Cannabinoids ought be afforded the same “presumption of safe prescribed use.”

    THC impairment is a cumulative concern that increases over time depending on the length and use of THC?

    We would be happy to see the studies that KR base this opinion on. We know of one massive resources employer that recently instituted a policy on prescribed THC that relied on this ground also (cumulative use). The argument is that over time, persons who consume THC on a daily/nightly basis become an impairment risk 24/7. This, to the best of our knowledge, is predicated on studies done in the mid 1970’s where chimps and other animal subjects were forced to smoke 70 joints a day. BUT, we’d be keen to see whatever studies Mr Stutley has viewed and adjust our views accordingly. It is not at all unsurprising that studies which made the subjects consume stupidly high-THC cannabis reported adverse outcomes for the trial participants.

    The overwhelming majority of medicinal cannabis patients are being prescribed cannabinoid ratios with nowhere near enough THC to replicate the exceedingly high doses of THC that the earlier cannabinoid research is predicated upon. Prohibition era scientists did a lot of work that doesn’t stand up to scrutiny against the measurable harm reduction results being achieved by doctors and other medical practitioners working in The Australian System of scheduled cannabinoids as medicines available via prescription.

    Right now, let’s take the hill in front of us. We at Drive Change are specifically looking for cases where medicinal cannabis patients are only consuming THC at night with the minimum 12-hour break (and solid sleep) before fronting up to work the next day (invariably fresher after a sleep on CBD:THC and without day-after benzo/sero/z-class fog).

    No-one, right now, would have buckleys of reasonable accommodations being made so they can consume an impairing dose (whatever that may be for that person) of THC on the job. Obviously for any manual job involving heavy machinery or heavy things moving on tracks at speed, this will always be out of the question. Whatever your prescription says, it is unconscionable to get high/medicated on THC when you’re working around other people in high risk environments. All it will take is one idiot to do this and other workers to die or be seriously injured and the cause of “Not Having to take SSRIs for the Rest of My Life” (with all the emerging risks that entails) will be set back years. That’s a cause example picked at random. There are hundreds of them that find their way to Drive Change the right to drive and the right to work so often comes down to one really shit choice:

    “Do I have to keep taking [X Inneffective and/or Dangerous Prescription Medicine] for the rest of my life in order to be able to hold down my source of income?”

    A Melbourne Storm Fan named Will Williams.

    The discussion on reasonable adjustments and what is/is not an unjustifiable hardship needs to be had.

    For the clerical and administrative and legal classes (office workers), meds that prevent you from operating heavy machinery ought be none of the bosses business when you solely punch a keyboard and click a mouse all day. There are 1001 ways to get out of fire warden duty so this risk is minimised for all parties concerned. One should always seek independent legal advice on these things and this article is most certainly not independent legal advice. Every worksite/office has an overlay of land law/lease restrictions and varied obligations to who can/cannot be on the premises.

    The Fire Warden Argument?

    This is literally the only THC and WHS issue that we can think of re white collar work/standard office environments. Perhaps Gerald from Accounts could be a risk if he puffed on a THC cartridge break on smoko, then accidentally spilt boiling hot coffee on Joan from HR. This West Aus piece frames it as being the sort of scenario that would require an employer to make unreasonable accommodations for a worker on prescribed THC by NOT making them the fire warden or a first aid officer. Let’s perhaps explore the class of persons ordinarily excluded from being fire wardens or first aiders (or temporarily excluded from acting in those capacities due to a temporary impairment). Let’s look at what sort of accommodations get made there and weigh up how much of a costs imposition they are.

    The THC and WHS risks for office environments are, from a workplace insurer’s perspective, likely to be treated same as alcohol. Firstly, in standard office environments, it is no more an employer’s business as to whether an employee has been prescribed an opioid or a cannabinoid. Secondly, the West Aus argument that medicinal cannabis creates an unjustifiable hardship on employers who need to rotate people on/off a First Aiders/Fire Warden roster is certainly headline grabbing.

    Vape cartridges on the sly combined with office drinks might get messy though. It might also result in people consuming much less alcohol and less boozy work culture all around. Who knows, this may result in greater productivity.

    What are the issues with WHS insurers and office environments?

    At the heart of it is the scenario where a white collar employer, by their conduct, acknowledges that a worker is on prescribed THC whilst at the same time knowing they have no sure-fire way to determine impairment should it ever become an issue should “shit happen.”

    IF there is a WHS issue, then this is going to be a risk. However, it’s not the inflated risk that West Aus makes it out to be in standard office environments. The fire warden thing is an outlier scenario.

    Two neuropsychiatrists and an interdisciplinary team to determine THC impairment?

    Again, would be keen to see whatever literature they base this one on but it honestly wouldn’t be surprising if a bunch of psychopharmacology-neuropsych boffins validated their own existence by creating a set of standards and procedures and published them with the barest skid mark of peer review.

    Irresponsible people who are stupidly high on THC during working hours will always get caught out by everyman detection methods. Smell, eyes and behaviour. How those initial conversations go are key for any worker should “shit happen.”

    Although roadside swabs have their own faults, we here at Drive Change have heard of employers within the medicinal cannabis industry going to the extra expense of acquiring high-end oral swab tests that can reliably detect THC consumed within the last 72 hours and combining those swabs with various forms of manual impairment testing. That is some progress at-least.

    It really isn’t an unreasonable expectation for employers to expect employees prescribed THC products to not consume them and come to work high.

    An inferential leap of confidence to read this into a one-liner medical certificate?

    Here is where we also partly agree with Mr Stutley. One liners or bare minimum letters stating the product names and dosages are not helpful. This is why the first step after a failed workplace drug test is to get the worker into an MC prescriber that has F2F capacity for the purposes of obtaining the sort of letter that lessens the length of the inferential leap that an employer is asked to take.

    Is it too much to ask in 2023 for employers to trust their employees will only consume their meds in accordance with the detailed instructions provided in a properly set out doctor’s letter? This has been the standard course of action for opioids, benzos, gabapentinoids etc. No one cares about SSRIs because so many people are on/off them at one point in time or another that society would collapse if everyone had to come off them. With the exception of acute withdrawal phases, it’s fair to presume that they are not ordinarily deemed impairing (even if you lock your keys in the car a dozen times in three weeks and regularly lose things). SSRIs make people forgetful and foggy. To the extent they become a WHS risk? Perhaps one day we will find out.

    Medical certificates involving a tick n flick done over the phone or online? Fair to query what kind of employer would accept that at face value without something else to provide a more fleshed out expectation about what the overall WHS risk would be. Products, dosage, timing. Product names like Super-Wizz-Bang-Cherry-Sherbert-Rainbow Kush do not help the cause of corporate-industrial integration of cannabinoid therapeutics also.

    However it’s grossly unfair to question the origins of the THC in a positive workplace drug test where a prescription is provided.

  • The Cannabis Industry’s Survival Depends on The Drug Driving Laws

    The Cannabis Industry’s Survival Depends on The Drug Driving Laws

    As medicinal cannabis becomes a more popular solution for patients and prescribers, it also becomes a bigger source of economic growth. Last month, industry leaders gathered together at the Australian Medicinal Cannabis Symposium to discuss triumphs and roadblocks of the budding medicinal cannabis industry. Drive Change lead and former magistrate David Heilpern was there to share his insight on how discriminatory drug driving laws are harming patients, public health, and economic growth.

    “This is an industry that’s starting to attract big business from funders who obviously see it as financially viable,” said David Heilpern, referencing medicinal cannabis investors, “I think they’re kidding themselves while these drug-driving laws are there.”

    road closed sign

    ALSO READ: Where Medicinal Cannabis is Legal, Roads Are Not More Dangerous

    Of course, it’s not just the industry that these drug-driving laws harm, but individual patients and entire communities. Most patients who deal with pain rely on driving to work or just living their daily lives. Though medicinal cannabis remains an illegal substance in the eyes of road police, other impairing pharmaceutical drugs–and drivers who take them–are well within their right to drive while using their medication.  These alternatives include benzodiazepines or opioids, both proven through extensive scientific studies to have a greater impairing effect on drivers than cannabis.

    david heilpern headshot
    David Heilpern is a staunch advocate for fair and equal drug driving laws.

    “If it was about road safety, it would apply to other prescription drugs,” Heilpern said of the current drug-driving laws before asking rhetorically, “so who wins from this?”

    The answer, of course, is clear. Pharmaceutical companies who make and distribute drugs like opiates, benzodiazepines, and other impairing drugs have monopolised the healthcare system for decades. For many years, these drugs were doctors’ and patients’ only options for combatting pain. We know better now.

    “Most people using medicinal cannabis were using pharmaceutical drugs to start with. And they’ll go back to them, even though the evidence is that those drugs have a greater impact on their driving.”

    David Heilpern

    According to the TGA, clinical studies have proven that patients who are prescribed medicinal cannabis report up to a 50% reduction in pain (especially for neuropathic pain, arthritis, and fibromyalgia); improved sleep and quality of life; and improved anxiety symptoms. Medicinal cannabis has also shown efficacy in reducing symptoms of epilepsy and muscular sclerosis, and it can alleviate the side effects of chemotherapy for cancer patients (although this practice is not yet approved in Australia).

    Many patients find better relief from their pain and discomfort when taking medicinal cannabis than traditional drugs, and enjoy a life free from the cumbersome side effects. Unfortunately, because of the law, they have no choice but to deny medicinal cannabis prescriptions.

    ALSO READ: Doctor, Patient, Advocate–A Physician’s Experience with Medicinal Cannabis

    “Patients go back to their opioids and they drive on the roads probably far more dangerous than they would have if they had taken that [medicinal cannabis] prescription,” he added. 

    Legislators continue to argue that medicinal cannabis is going to be a problem–but places where it is legal prove the opposite. We don’t even have to look far to see the effects of legal prescription cannabis in drivers. Tasmania legalised medicinal cannabis on the road in 2020. 

    They have seen no increase in road toll since. 

    How can we catch up on the mainland? Now that the tides have changed in government, we might have a chance to have our cause heard. 

    Now more than ever it’s important to write to your local member. Let them know how the drug driving laws affect you, your family, or your loved ones, and direct them to scientific research to back your claims. 

    You’ll find all the details you need on our BetterLetters campaign page. All you need to do is send the letter and start urging them for change. 

    If Tasmania can do it, so can the rest of Australia.

  • Announcing the Drive Change Roundtable for Government Officials

    Announcing the Drive Change Roundtable for Government Officials

    As you may have seen, we’ve been encouraging the cannabis community to write letters to local members of Parliament. A major part of that campaign is to drive local MPs to the upcoming Drive Change Roundtable for Government officials.

    What is the Roundtable?

    This Roundtable will serve as a platform to address the discriminatory drug driving laws that are currently in place for medicinal cannabis patients. It is only open to MPs and Government Officials, giving them a chance to learn about and discuss the community’s call for change in a private forum.

    Read more: THC in blood and saliva not indicative of impairment, studies say

    When is it?

    The Roundtable will take place on Tuesday, 29 March 2022. 

    Leading up to this date, we are calling on community members to take a moment to tell their personal stories to MPs through letters. These letters are also an opportunity for the community to encourage MPs to attend the Roundtable.

    By bringing your stories to their attention, they can bring your experience to the table. This is how change is made. 

    Why host a Roundtable?

    It’s important that this cause is discussed amongst those who can make change happen. Letting your MPs know why drug driving law reform is important to you is a step towards enacting more fair and equal drug driving laws for cannabis patients. 

    Read more: Letter to Local Members: how you can write a compelling letter to inspire law reform

    As a patient or concerned citizen, how can I encourage MPs to go?

    Write a letter to tell them your story, explain why reform is important to you, and provide details about the Roundtable. Attending this virtual, government-only event is their opportunity to show they are listening. Giving these officials a time and place to discuss it can be an effective means for getting law reform discussed in Parliament. 

    We provide two ways for your to write a letter:

    1. Via an email on the Drive Change Do Gooder site
    2. Via a physical letter via the Drive Change Better Letters tool.

    Who’s Going?

    In addition to all government attendees, the Roundtable will also feature voices from healthcare, science, and law enforcement. These industry leaders all provide a valuable perspective on how the drug driving laws impact the community.

    Teresa Towpik speaks from the perspective of a doctor, patient, and cancer survivor. When it comes to medicinal cannabis, she believes the laws are causing significant harm to people dealing with pain and illness in our society.

    Read more: Ignorance Isn’t Bliss, Knowledge Is

    Dr Thomas Arkell Cannabis and Driving Research Expert working within the was previously a research candidate at the University of Sydney, where he earned his doctorate. Now he is a Research Fellow at Swinburne University. 

    Read more: Scientific Research: Cannabis Vs. Other Drugs & Driving

    Mick Palmer is a former commissioner of the Australian Federal Police. Reflecting on his career, he sees the driving laws as unfit-for-purpose and ends up punishing people already coping with a terminal illness or serious pain.

    Read more: One Size Does Not Fit All: Mick Palmer and the Need for Fit-For-Driving Laws in Australia

    David Heilpern is an ex-magistrate, lawyer, adjunct professor, and the Drive Change campaign lead. He spent 21 years in Parliament, having been the youngest ever elected member, but left when he found there was too much restraint when it came to speaking out about drug driving law reform. 

    Read more: Open Letter to the Department of Transport and Main Roads: Are You Really Paying Attention to Road Safety?

    Fiona Patton (MP) is a leader of Victoria’s Reason Party. She is a vigorous voice in government for drug law reform and has submitted several proposals to the Victorian Parliament championing decriminalisation, cannabis for personal use, and drug driving law reform.

    It’s time that Parliament hears the community’s support for drug driving law reform. Write your letter now and urge them to join the conversation with these industry leaders on 29 March.

  • These Two Bills Could Be Crucial for the Future of Medicinal Cannabis

    These Two Bills Could Be Crucial for the Future of Medicinal Cannabis

    Last year, we saw our ambassador Cate Faehrmann call on officials to throw out all the roadside drug tests in Nimbin during Mardi Grass weekend, citing contamination. Now, she’s taking an even bigger swing at the unjust drug driving laws with the introduction of two new bills, and one of them may help us see our goal of more effective laws being realised.

    The Road Transport Amendment Bill

    The “Road Transport Amendment Bill” aims to give medicinal cannabis patients the same rights as any other patients in Australia who take prescription medicine. This means that they will not be penalised for driving if they have a valid prescription and can prove they are not impaired–the rights that all other patients also have.

    Writing a letter can be critical for the outcome of this debate in parliament.

    Cate Faehrmann’s stance on drug laws in Australia align with the work of Drive Change.

    A member of the Greens NSW, Cate Faehrmann is a vocal proponent of drug reform. She has introduced several bills throughout her career, but this one truly gets to the heart of the matter for medicinal cannabis patients and their rights to drive, something she says is “long overdue and increasingly urgent.”

    This bill would amend our current driving laws, making them safer than they currently are and giving rights to medicinal cannabis patients. Drivers today are limited to medical options, like benzodiazepines, opiates, and morphine–which pose an even greater threat to road safety.

    “I urge the Government and Opposition to assess my bill with compassion and common sense.”

    Cate faehrmann, MP

    “Roadside drug tests are incredibly sensitive. Patients can test positive 24 hours or more after they have consumed cannabis, well after any impairment has worn off.”

    Cate Faehrmann uses scientific research to support the latest bills, and states: “This bill would simply provide the same medical defence that is already given to morphine patients. Medicinal cannabis is far safer than morphine on and off the road, but medicinal cannabis patients who test positive face damaging drug driving charges.”

    If it passes, this bill will finally grant legal defence to medicinal cannabis patients who test positive in roadside tests, so long as they are within their legal rights and they are not impaired. Currently, the only state which grants this protection to medicinal cannabis patients in Tasmania.

    Seeing this bill brought to the government means we may be able to see change soon, but it’s not guaranteed yet. 

    “It should have happened when medicinal cannabis was legalised at the federal level in 2016,” Cate Faehrmann says. “Instead medicinal cannabis patients have been discriminated against and forced not to drive because our laws haven’t kept up.”

    What you can do to show support

    As the government deliberates their stance on this bill, the community can urge them to enact the change we desperately need. Writing to your local MP is one way to ensure they know the community supports the implementation of these amended driving laws. 

    >Click here to get started!<

    In conjunction with the Road Transport Amendment Bill, Ms Faehrmann also introduced the Cannabis Industry Bill 2021. This second bill aims to legalise medicinal cannabis for personal use. Though this would be an important step forward, protecting existing medicinal cannabis patients, many who have long been dealing with discrimination on the roadsides, is where we need to keep our focus.

    Both of these bills will be up for debate in 2022.

  • Answering Cannabis Law FAQ

    Answering Cannabis Law FAQ

    With cannabis available via a prescription in Australia since 2016, both doctors and patients are increasingly more likely to consider it as part of a healthcare practice.

    Medicinal cannabis is already widely prescribed for conditions including PTSD, chronic pain, anxiety, and insomnia. Although the health industry generally agrees with its medicinal merits, the driving laws still classify cannabis as a criminal substance.

    Campaigns like Drive Change exist during this transition phase to help shape what drug driving laws will eventually look like.

    Mat Henderson

    This brings a lot of questions into view for patients who are prescribed medicinal cannabis, those who are interested in it, and the doctors who prescribe it. Some of the most persistent and important questions surround exactly how legal medicinal cannabis fits into the framework of current drug driving laws.

    This was the focus of our first webinar, an Ask Me Anything-style event titled Ending Discrimination: Medicinal Cannabis & Drug Driving Questions Answered. With a panel of experts and a community of supporters, the conversation revealed a lot of confusion around medicinal cannabis’ legal standing on the roads.

    These common questions give some insight into how the laws work currently, and how we plan to see them change.

    Here’s a list of the questions in case you want to jump ahead:

    Measuring THC Impairment

    Q: Why won’t politicians accept the science regarding THC and impairment, as they did for drink driving?

    A: There are several reasons, most of which are residuals of the War on Drugs. Police are resistant to change roadside THC detection procedure. Even if they would consider it, there is currently no way to accurately measure someone’s impairment on THC as we can with alcohol.

    There is also the pharmaceutical industry and lobbyists to consider. Big Pharma is king, and revisiting drug driving protocol would inherently mean putting benzo/opioids under the same microscope–something that no one wants to do for fear of ruffling feathers. Unless a corporation is willing to put the science of medicinal cannabis in front of legislators, it will likely remain under the radar. -Mat Henderson

    Q: How developed are technologies to test for impairment? Are there any examples of such technologies used overseas? Are there better ways to test for impairment rather than RDTs?

    A: Yes, we had an interesting session with the creator of DRUID. Check it out.

    Cannabis Patients Rights and Limitations

    Q: Why can’t patients be given a medical card and/or use relevant TGA approvals to protect them at RDT?

    A: It should be possible, but first we would need a change in the law. And that’s what we are striving for. –David Heilpern

    Q: Are there documents or laws we can cite that will protect those of us that use this medicine responsibly?

    A: Sadly, no. Mere presence without impairment is still presence and that’s all that matters under existing laws. – Mat Henderson

    Q: Can TGA create a database of current patients for police, or would this be a breach of privacy and information?

    A: It would be easy to set up with the patients permission, but can only happen if the law changes. -David Heilpern

    Q: Do you think it’s possible that we will see a National approach to driving laws and driving law reform anytime soon?

    A: Within the next ten years or not at all. – Mat Henderson

    Q: Is there any legal standing for patients to deny a RDT?

    A: Like Random Breath Testing (RBT) for alcohol, you can be charged as if you failed the RDT if you deny taking one. -David Heilpern

    Q: How long does a drug driving suspension apply?

    Suspensions vary from state to state. You can check your local guidelines here

    Policing Medicinal Cannabis

    Q: Why does the law target THC when there are so many other legal or illegal substances which cause worse impairment?

    A: Simply because of the historical hangover from the War on Drugs where THC was primarily associated with recreational cannabis. This association still exists. We are living through a transitional era where the law will eventually align with the new reality that THC is also a prescribed medication. Precisely what that regime eventually looks like is anyone’s guess, but campaigns like Drive Change exist during this transition phase to help shape what those laws will eventually look like. – Mat Henderson

    Q: Is it fit and proper for police to be advocating for the law and to determine public policy on health outcomes?

    A: There is no problem with the police union speaking out, or the police minister. That is their role and function. However, police are meant to apply the law, not comment on it. It is our opinion that these comments ought not be aired in public. What politician would have the guts to go against the police? The police know this, and use their power. It is wrong. -David Heilpern

    Q: Why do the police have vested interests in keeping these current laws and how can we better educate them?

    A: The police in NSW get a budget allocation directly from Road Safety to administer the tests, thus the police have a vested interest. -David Heilpern

    How to Help Drive Change

    Sign the petition, which helps us to prove to lawmakers how much support is in favour of drug driving law reform.

    You can also help support the ongoing cause by donating to Drive Change.

  • Dr Teresa Towpik: “Ignorance Isn’t Bliss, Knowledge Is.”

    Dr Teresa Towpik: “Ignorance Isn’t Bliss, Knowledge Is.”

    This article is written by Drive Change ambassador Dr. Teresa Towpik. Below, she shares her experience with the drug driving laws from the standpoint of a medicinal cannabis doctor and patient.


    January 2016–what a month it was for me. 

    I didn’t realise it then, but this would mark the beginning of a new chapter in my life. This was when I first heard that cannabis was going to be legalised for medicinal use. 

    At the time, I was extremely surprised. I didn’t even really understand cannabis. To me it was better known as marijuana, a drug of addiction; dangerous and to be avoided. 

    However, once I started to do my research, I realised how wrong and ignorant I had been. 

    It soon became clear to me that I was now dealing with an amazing herb that has incredible medicinal and healing properties. I felt touched and inspired by patients’ stories, especially children suffering from intractable epilepsy. I began to see cannabis as a sophisticated plant.

    In learning all this, I discovered that I wasn’t able to be passive and conveniently wait for others to speak up about this. I decided to become an advocate of cannabis and committed to long hours learning about this plant. 

    Real-World Use

    I made the decision to become involved in prescribing cannabis as a doctor. It was a difficult process to begin, because the access to cannabis was cumbersome and convoluted. It required hours of paperwork that turned into countless rejections from both TGA and NSW Health State Department. 

    I first applied to the TGA when I had a patient who suffered from Parkinson’s disease. The application to prescribe was approved by the TGA in September 2017, but NSW Health kept rejecting it. There was a lot of back and forth, even a solicitor was involved.

    Finally, in March 2018, I got my approval. It seemed the floodgates were open, and after that every application was approved within 48 hours.

    Since then, I have prescribed cannabis for many patients and have observed how it changed them for the better. Many of my patients became more functional, alert, and active. A few of them even said to me “my brain is not so foggy anymore.” 

    I have seen firsthand the positive effects cannabis has on these patients. For many of them, cannabis offers a return to normalcy, reinvigorating their functionality, motivation, and inspiration in life. It’s the key for them to return to working jobs, socialising, and living a full life.

    Cannabis and Road Safety

    Unfortunately, there is a very significant roadblock to improving patient outcomes through prescribing medicinal cannabis in Australia. That roadblock is the discriminatory and unfair drug driving laws on medicinal cannabis patients.

    These laws are causing significant harm to many people dealing with pain and illness in our society. Many of these are people who have exhausted various therapeutic options in treating their condition with no success. Eventually, they come to think and feel that they are forgotten by the health system.  

    Medicinal cannabis makes it possible for patients to leave behind days of taking 10-20 different medications, many of which reportedly makes them feel like zombies.

    Some patients said that there were instances where they wouldn’t even remember how they managed to get from point A to B when driving on conventional prescription medicine.

    I have had many patients comment that they became better drivers while taking cannabis. As a doctor I had to ask myself: what do I do in this situation? Should these people be reported for breaking the law?

    Doctor, Advocate, Cannabis Patient

    Through my professional experience I can tell you that the current drug driving laws limit clinical decisions. For many practitioners, the choice is often based not on what patients need, but on what the driving laws allow. Unfortunately, the laws don’t quite make sense. 

    Roadside tests currently screen for THC in the system as defined by a mouth swab. Any amount present is considered a criminal act. However, there is clear scientific evidence which proves the level of THC in the system does not correspond with impairment. If it did, I might be classified as a criminal myself.

    medicinal cannabis is a legal way to treat many illnesses.

    In 2001, I was diagnosed with metastatic breast cancer. In May 2019, we discovered it was recurrent.

    To cope with the effects of my cancer treatment, I have been taking significant doses of cannabis for the past 2 years. When I am not impaired, I have been driving. It is extremely unfair to know that the system labels me a criminal in this situation.

    I am aware of the law’s zero-tolerance for THC, even for medicinal cannabis patients, but the fact is that I need my car to function. This is a situation that many patients experience in their lives, and no one is exempt from roadside drug testing.

    I was drug tested on my way to Nimbin on 2 May of this year. Aware that this was a risk, I skipped my cannabis medication for 2 days before my trip. Still, my heart sank when I was stopped by the police. A lot went through my head, all the possibilities and consequences of me possibly testing positive. The fact that I have to deal with living in fear of being penalised for dealing with my condition feels terrible.

    We know that cannabis is fat soluble and can stay detectable in the system much longer. Luckily, I tested negative. For me the trace amounts of THC was gone in two days, but this time frame varies by person, in part due to the rate of metabolism. I was not impaired and my driving record remains in good standing, but many patients feel like they are constantly at risk of losing their license. Patients have also told me that they feel more alert on medicinal cannabis than other drugs, yet they still face penalisation for the former. Feeling more alert makes sense because cannabis is proven to have a lower crash risk than many other drugs.

    As a doctor and cannabis patient I am now standing up to the government in favour of appeal of these unfair laws and this unfair situation. Until this happens, I’m left with the question: is it moral to obey immoral laws?


    To help change these unjust laws, please sign the Drive Change petition.

  • 4 Questions That Uncover the Problem With Our Current Drug Driving Laws (& Medicinal Cannabis)

    4 Questions That Uncover the Problem With Our Current Drug Driving Laws (& Medicinal Cannabis)

    This article is written by Drive Change ambassador Michael White. Below, he shares his experienced insight and analysis of recent data on medicinal cannabis and its effects on driving.


    As a person who has been involved in drug-driving policy and research for over 25 years, I have recently been asked to provide answers to the following four questions in relation to the road-safety implications of driving after using cannabis. 

    These are probing questions that get to the heart of the matter. They are the questions that policy makers need answers to, if they are to develop evidence-based policies in relation to driving after the use of cannabis.

    Q1. Does research show that risk of crashing when there is THC in the bloodstream are significantly higher than when there is no THC in the bloodstream (based on an unbiased odds-ratio calculation)? 

    My answer is ‘no’ – when study biases are taken into account. 

    In other words, the presence of THC in the blood is not associated with a higher risk (odds ratio) of crashing. To come to this conclusion I reference a recently completed epidemiological review1 of the cannabis-crash literature that I have co-authored with my colleague Prof Nick Burns (White & Burns, 2021), which is that the null-hypothesis (cannabis-crash odds ratio = 1.0) cannot be rejected. 

    However, that statement of our conclusion is, of course, compatible with the true odds ratio being slightly greater than 1.0 – such as 1.2. However, my opinion is that the true odds ratio most probably really is 1.0. 

    Q2. Does research show that driving performance is degraded when there is THC in the bloodstream compared to when there is no THC in the bloodstream?

    Yes, so we have a problem. 

    Why does the degradation of performance (impairment) not increase the cannabis-crash odds ratio? There are many things to be taken into account. Cannabis users are not inclined to drive soon after using, especially if they feel intoxicated. Cannabis impairment is generally weak, and probably normally below a threshold where driving performance is dangerously degraded. 

    Furthermore, while there could be a small increase in crash risk due to impairment, it is probably balanced by a small decrease in crash risk due to more cautious driving (as demonstrated by slower travelling speeds and greater headways).2

    Given the role of speed in crash causation, a little extra caution could go a long way. Nick Burns and I are working together again to review the literature of the impairing effects of cannabis.

    Q3. If medicinal cannabis has effects on driving performance, then is there a time window after ingestion of THC when impairment is most likely to degrade driving performance? 

    Yes, there is a time window. Its duration has been explored in a couple of recent reviews.3 4 The most conclusive evidence we have so far is this:

    For smoked cannabis, it is probably about three hours from the moment it is ingested. For edibles, such as cookies, it is probably a bit longer, starting after a delay of at least half-an-hour. The two aforementioned reviews also indicate that low-level impairment can, in some cases, last beyond three or four hours.

    Q4. Does a performance-based test exist which can measure any decrease in performance that might arise from having THC in the bloodstream?

    No. There is too much individual variation in any performance tests and too much individual variation to be able to accurately gauge levels of THC impairment. However, the answer could possibly be ‘yes’ if baseline levels of performance could be established for individuals. 

    Still, even then, the measured performance decrement due to THC would probably be irrelevant to crash risk.  

    There is a smartphone app known as the ‘DRUID test’ that seems to be popular in some quarters for measuring driver impairment. A recently published paper that includes an evaluation of the test can be viewed from the journal’s website here.


    1. For a copy of this review, please email a request to mawhite8@internode.on.net.
    2. White, M. A., & Burns, N. R. (2021). The risk of being culpable for or involved in a road crash after using cannabis: A systematic review and meta-analyses. Submitted for publication.
    3. Eadie, L., Lo, L. A., Christiansen, A., Brubacher, J. R., Barr, A. M., Panenka, W. J., & MacCallum, C. A. (2021). Duration of neurocognitive impairment with medical cannabis use: A scoping review. Frontiers in Psychiatry, 12, Article 638962.
    4. McCartney, D., Arkell, T. R., Irwin, C., & McGregor, I. S. (2021). Determining the magnitude and duration of acute delta-9-tetrahydrocannabinol-induced driving and cognitive impairment: A systematic and meta-analytic review. Neuroscience and Biobehavioral Reviews, in press.
  • For Blake, Queensland Drug Driving Laws are Unreasonable

    For Blake, Queensland Drug Driving Laws are Unreasonable

    Blake is sharing his experience as part of our “Personal Stories” series, which invites medicinal cannabis patients to share with the community how drug driving laws are impacting their quality of life. If you’d like to share your story, please email us at hello@drivechangemc.com.au


    It’s time that medicinal cannabis patients in Queensland are given driving defence. 

    I’m a medicinal cannabis patient, and every day I worry that if I were to get drug tested that it would screen positive. 

    It’s not fair that I should have to worry about this, since using my medicine doesn’t mean I drive when I’m impaired. Having access to medicinal cannabis has been a godsend for my condition, but knowing about the consequences if I test positive in a drug test only brings anxiety.

    I use medicinal cannabis to treat my bipolar disorder. I’ve grappled with this for a long time, and access to medicinal cannabis has helped to save my life. 

    However, the laws make it seem like the system still doesn’t accept medicinal cannabis. It’s unreasonable to suggest to people who use medicinal cannabis that they can “just go without for a few days” to be able to drive. The laws should take into account having THC in your system doesn’t mean you’re impaired.

    I have the proper paperwork from the TGA, stating that THC may take up to five days for most of the THC to leave your system. To be able to work, I can’t wait that long before driving again. These laws are keeping me out of work and struggling to earn an income. If I choose to drive anyway, I am at risk of losing my license, even if I’m not impaired. It’s just not fair.

  • Open Letter to the Department of Transport and Main Roads: Are You Really Paying Attention to Road Safety?

    Open Letter to the Department of Transport and Main Roads: Are You Really Paying Attention to Road Safety?

    David Heilpern wrote a letter to the Land Transport Safety and Regulation department inquiring about the state of the current laws and in light of the research showing their ineffectiveness. The General Manager, Mr Andrew Mahon, answered this inquiry in a letter which we have attached below for reference.

    The following is an open letter to Sussan Osmond, who Mr Andrew Mahon advised Drive Change to contact for further correspondence.

    Dear Sussan Osmond,

    I recently wrote to the Department of Transport and Main Roads expressing my concern over the ineffective and discriminatory drug laws in place for drivers. In this letter, I will address the Department of Transport and Main Roads directly.

    What I presented to you was a concise report on how our drug driving laws are failing to improve safety as they discriminate against medicinal cannabis patients. While I appreciate your effort to offer a response, they were mostly evasive of the problem and prove that lawmakers aren’t relying on science or fact to formulate these laws. They are in need of an update. 

    In your response, you went as far as to agree they are “difficult to address” but failed to present any scientific evidence in support of the need to uphold the current jurisdiction. This proves a clear need for deeper understanding of the issue. I will provide that to you, and the wider community, here. 

    Cannabis as a drug

    Cannabis is a drug that is proven to impair cognitive and motor function.

    Mr. Andrew Mahon, Land Transport Safety and Regulation), QLD

    In your letter, you address cannabis as a drug that is “proven to impair cognitive and motor function.” While this is true, it does not explain why the driving laws permit drivers to use other TGA-scheduled and over-the-counter drugs while operating vehicles. 

    This is the true crux of the issue between medicinal cannabis and roadside drug tests. The chemicals in pharmaceutical drugs can be detected with such tests. Conversely, cannabis can remain at detectable levels in these tests far beyond the time of impairment. This clearly points to current practices as the problem. Why are we still using outdated methods for roadside drug testing if we know without a shadow of a doubt that they’re unreliable?

    That truth is that yes, cannabis is a drug. The wider truth of it is that there are plenty of drugs which get protection or a pass when they are detected in roadside tests. It is nothing short of discriminatory to deny such rights to medicinal cannabis patients, especially when you consider the effects on road toll.

    This has been an area that has been studied, and the results speak for themselves. The crash risk rate of drivers with a legal 0.05 BAC is 1.38-1.75. Once the BAC hits 0.08, this risk rises to 2.69. This is by far the highest crash risk rate of any of the other “impairing substances.” 

    Crash-risk-crash-culpability-estimates-drug-classes
    Medical cannabis and driving, by Thomas R Arkell, Danielle McCartney, Iain S McGregor, doi: 10.31128/AJGP-02-21-5840

    Opioids are not far behind, presenting a crash risk of 2.29; Benzodiazepines carry a risk up to 2.30. Even antihistamines carry a crash risk of 1.17. So why then, if cannabis carries a crash risk of 1.11-1.42, is it the only of these drugs to be banned on the roads?

    Discrimination, again, seems to be the only plausible answer. 

    These discriminatory laws seem to be rooted in an outdated and unreasonable vilification of cannabis, one that doctors and scientists are committed to re-educating the public on. In some capacity, the government is already on board, having approved medicinal cannabis for therapeutic purposes, and there are 75,000 patients in Australia with legal prescriptions.

    While these medical professionals have done their due diligence, there has been no accountability from the Department of Transport and Mains Roads, nor the police, in understanding that cannabis as a legal drug holds value in public health. 

    Driving and Road Safety 

    The role of drugs, in varying forms, is a growing problem for road safety, not only in Queensland but nationwide and internationally

    Mr. Andrew Mahon, Land Transport Safety and Regulation), QLD

    The TGA has categorised some forms of medicinal cannabis as a Schedule 8 Controlled Drug. Also in this class are Oxycontin, Sativex, Amytil, etc. So, why is it that patients who test positive for these conventional medications are not committing a crime while medicinal cannabis patients are?

    In your letter, you mention that “The role of drugs, in varying forms, is a growing problem for road safety, not only in Queensland but nationwide and internationally.” I absolutely agree with you on this point, which is why I am so adamant about adjusting the laws surrounding them. 

    The studies into road safety measures speak for themselves in this matter. After the introduction of seatbelts, there was a marked decline in road deaths. Likewise with airbags. In terms of roadside testing for cannabis, there has been no evidence that this decreases road toll. This points to the fact that we need newer methods of understanding what leads to crash risk. 

    A “zero-tolerance approach” to selected legal prescriptions is clearly not the answer. 

    You mention that we “take a zero-tolerance approach through presence based legislation as opposed to setting limits similar to alcohol,” but this argument is also untrue and shows the lack of research that’s been done on this topic. Tasmania has adopted laws protecting medicinal cannabis patients on the road. It proves that it is being done here in Australia and can be done throughout the entire country to defend medicinal cannabis users without a toll on road safety.

    Yes, impairment increases risk of motor vehicle crashes–which is exactly what roadside drug tests should be looking for. You seem to understand this, saying that “impairments that will affect a person’s driving include their ability to anticipate hazards and unexpected situations, their decision making and their ability to respond quickly to changes in the traffic environment (e.g. reaction time).”

    I ask again – why can other potentially impairing pharmaceutical medicines get a pass in roadside tests? Additionally, in testing for the presence of THC, which remains detectable past the point of impairment, it seems that there is no real evidence to back your claim that this is in the name of road safety when other harmful drugs are permissible and protected. 

    The bottom line on mouth swabs is that they do not work. If they did, we would not have seen a 55% increase in road crashes between 2012-2018.

    I do agree with you on one point, that medicinal cannabis cannot easily be tested at the roadside. The legislation stops short of the true issue: what can we do that can make road safety a priority, without a discriminatory framework that infringes on public health?

    New and Improved Methods

    The answer is not as elusive as you state it to be. In actuality, a simple impairment test can be completed. This has been successful  in jurisdictions around the world. It has even caught up to the technological age, and apps such as DRUID app takes the guesswork out of it. Why is it that the Australian governments want to hold on to archaic methods of testing for drug impairment. It seems odd to want to do so when the equipment is so expensive and road toll even more costly both financially and from a human perspective. 

    I myself am acutely aware of these facts. But the truth of the matter is that the law is changing as our society begins to understand how to better care for our people. This is apparent when you consider the doctors, scientists, and lawyers who prescribe medicinal cannabis and/or support changing these discriminatory laws.. What is not apparent in your letter or in the law is why the Road Commission remains incredibly hesitant to take the step forward not only to assist in public health and putting an end to discrimination, but also into ways that have already proven capable of making our roads safer. 

    We are calling on your department and other governmental organisations and those in Parliament to research the facts. This is integral to the protection and progression of Australian medicine. This is about public safety and the knowledge of the facts to help improve public health and safety. 

    I trust this has given you some facts you may not otherwise have known.

    The Drive Change team and more importantly patients who desperately need your assistance will await your response on this matter.

    Yours sincerely, 

    David Heilpern
    Director of Change
    Drive Change

    The original letter sent to Drive Change can be found here.

    The letter above is a slightly edited copy (due to the different medium) of this letter.

  • One Size Does Not Fit All: Mick Palmer on the Need for Fit-For-Purpose Driving Laws in Australia

    One Size Does Not Fit All: Mick Palmer on the Need for Fit-For-Purpose Driving Laws in Australia

    This article is written by Drive Change ambassador and former Commission of the Australian Federal Police, Mick Palmer. Below, he shares his take on where the laws need improvement to protect medicinal cannabis patients and the community on the road.


    There is a clear and well-understood correlation between impaired driving and road safety. Australia’s road toll is of broad community concern, and the Government’s effective policies–like the .05 drink driving legislation and speed cameras– should be applauded. However, Australia’s ‘zero-tolerance’ drug driving policy creates trouble for both patients and police. 

    “Fit-for-Purpose”

    The government has already allowed for doctor-approved access to medicinal cannabis. This comes in response to the ever-growing scientific evidence, in addition to anecdotal evidence, that medicinal cannabis provides relief for people experiencing genuine pain and suffering due to a range of health issues, including terminal illness.

    The government’s recognition of this evidence provides a step toward relief for thousands of Australians. However, for the legality of medicinal cannabis to fully operate as intended, the roadside drug testing protocol urgently requires amendment. 

    I am not suggesting impaired driving laws should be weakened, but rather that they are updated to fit-for-purpose and aimed at achieving intended outcomes. 

    To become fit-for-purpose, retain credibility, and operate fairly, driving laws must be aimed at dealing with impaired driving. Until this happens, many law-abiding Australians suffering from illness and often extreme pain will continue to experience legal and physical distress as a direct result of the discriminatory drug driving laws. 

    “Police Leniency”

    Likewise, police have a clear responsibility to effectively manage and apply the legislation in the community interest. The truth is that police exercise considerable compassionate discretion in their enforcement of drug driving laws every day. This is, in part, due to the driving laws being unfit-for-purpose and in need of review and amendment, or repeal.

    The role of the police is to enforce laws, not make them. It is certainly a recipe for inconsistency to expect the police to cure legislative deficiencies by making personal judgments on patients. 

    Furthermore, if police are screening for medicinal cannabis use but not for impairment, the laws are unfit-for-purpose and end up punishing people already coping with a terminal illness or serious pain.

    Medicinal cannabis patients should not need to rely on the favourable exercise of discretion by police to escape punishment. It is up to Governments to have the courage and decency to legislate the necessary changes.

    “Necessary Changes”

    If there is any chance that medicinal cannabis can help people with terminal illness or serious pain, to lessen their pain and suffering and improve their quality of life, we should, as an educated and compassionate society, do all that is reasonably possible to facilitate access. 

    The fact that these current drug driving laws exist is sufficient for many patients who qualify for medicinal cannabis treatment to decide not to take their medication. 

    Some of these patients need to drive their motor vehicles as a matter of daily necessity. Sufferers should not be forced into situations where they may end up breaking the law to gain relief. Surely this is not the government’s intention.

    The reality of current roadside testing is that they are not only discriminatory, but also invariably lead to further distress, fear, and embarrassment for the patients.

    The resulting pain and suffering achieve the exact opposite of the intention of Governments in allowing legal access to medicinal cannabis in the first place. I am personally confident that this also is not the intention.

    The facts speak for themselves. There is a better way to uphold law and road safety. We must be prepared to explore the options. 

    As an example, Norway has successfully been assessing drug levels in driver’s systems for many years. This surely is far preferable to the continuation of a “zero-tolerance” approach that we have here, which can only be beaten by judicial discretion.

    The current medicinal cannabis drug testing laws need to be subject to urgent review. By amending the laws, we move to ensure they operate fairly and without discrimination while continuing to achieve the intended outcome of controlling impaired and potentially dangerous driving.

  • Scientific Research: Cannabis Vs Other Drugs & Driving

    Scientific Research: Cannabis Vs Other Drugs & Driving

    Recently I co-authored an article called Cannabis & Driving, which was published in the Australian Journal of General Practice. The report reviewed the scientific evidence regarding cannabis and driving impairment. It also discusses the legal issues affecting patients and physicians.

    The findings lead us to conclude that medicinal cannabis should be treated the same way we treat all other potentially impairing medications.

    I’ve written this short article to summarise the findings for Drive Change, supporters of the campaign, and those fighting for equal rights for medicinal cannabis patients.

    THC vs CBD

    THC, put simply, is the part of cannabis that can get you stoned. It is used to treat a range of conditions, including chronic pain and chemotherapy-induced nausea and vomiting. 

    On the other hand, CBD is non-psychoactive, which means that it doesn’t get you stoned. It is used to treat anxiety, psychosis, and some neurological disorders.  

    When combined with THC, CBD may help reduce some of the adverse side effects of THC (e.g., anxiety and paranoia). However, this does not mean that CBD decreases the impairing effects of THC.

    Cannabis and Driving

    Scientific research shows that cannabis can impair driving ability and certain cognitive functions such as divided attention and working memory. These effects, however, are relatively mild and disappear as the body metabolises THC. 

    Comparing cannabis and other drugs

    When it comes to driving, current evidence indicates that a driver who tests positive for cannabis is approximately 1.1-1.4 times more likely to be involved in a crash relative to a sober driver. 

    To put this into perspective, a driver with a legal blood alcohol concentration of .05 is approximately 1.3-1.8 times more likely to be involved in a crash relative to a sober driver. 

    And a driver who tests positive for benzodiazepines (e.g., Valium) is approximately 1.2-2.3 times more likely to be involved in a crash relative to a sober driver.

    It is important to remember that these are just estimates; these numbers could be higher or lower in reality. In a recent study of ours that looked at real-world driving performance, participants who had vaporised cannabis tended to have a very similar level of impairment to what we would expect to see in a driver with a BAC of .05. 

    There is no evidence that CBD impairs driving at all.

    What About Medical Cannabis?

    Almost all this evidence comes from studies involving healthy volunteers who use cannabis occasionally. We know that people who use cannabis more frequently (e.g., daily) show less impairment than occasional users when given the same dose of THC due to the development of tolerance. 

    Patients consuming cannabis daily and at doses that are therapeutic rather than intoxicating may be even less impaired. This is especially true if their cannabis use relieves an underlying condition that can impair driving, such as chronic pain. Research is currently underway to test this hypothesis. 

    Conclusion

    Overall, cannabis (and THC, specifically) appears to have a relatively minor impact on driving performance. 

    However, it can produce significant impairment in certain situations, such as when combined with alcohol and when used by people who are unfamiliar with its effects. 

    Patients who are using medical cannabis should be aware of these considerations and remember that it is illegal to drive if you have any detectable amount of THC in your system. In addition, you may still test positive for cannabis even if you are not impaired. And, having a valid prescription for medical cannabis does not exempt you from current roadside drug testing laws.

  • Drive Change Submission to NTC: Assessing Fitness to Drive

    Drive Change Submission to NTC: Assessing Fitness to Drive

    On the 11th of June 2021, the Drive Change Team responded to the National Transport Commission’s Assessment of Fitness To Drive Interim Report public consultation.

    We were lucky to have a majority of our Ambassadors, Supporters and Friends sign on to the submission, which we believe shows great support for ending discrimination toward medicinal cannabis patients. Here are the organisations and individuals who supported our submission:

    Drive Change NTC submission friends ambassadors and supporters

    Submission Summary

    The proposed recommendations state that healthcare practitioners are to determine a medicinal cannabis patient’s ‘fitness to drive’. This recommendation aligns with the current guidelines for all other prescribed potentially impairing medications such as opioid analgesics and benzodiazepines.

    It does not change the liability of the healthcare professional from the current state. 

    And, like all other medications, the doctor makes the initial assessment, but it is the patient’s responsibility not to drive whilst impaired.

    The Drive Change Team, and all parties involved in the submission, agreed with the proposed recommendations. Passing these guidelines and amendments would be seen as a federal recommendation to create equal rights for medical cannabis patients. 

    To read the complete submission, you can view or download the NTC Submission PDF.

    Thank you to all of our Ambassadors, Supporters and Friends for their continued support toward making changes to these discriminatory drug driving laws.